Volume 24, Issue 1 (April & May 2021)                   J Arak Uni Med Sci 2021, 24(1): 98-107 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ranjbaran F, Jamilian H R, Sadeghi Sade B. The Effects of Allopurinol on Major Depressive Disorder. J Arak Uni Med Sci 2021; 24 (1) :98-107
URL: http://jams.arakmu.ac.ir/article-1-6399-en.html
1- Department of Psychiatry, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
2- Department of Psychiatry, School of Medicine, Arak University of Medical Sciences, Arak, Iran. , mjamilian@yahoo.com
3- Department of Social Medicine, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Abstract:   (1769 Views)
Background and Aim: Major Depressive Disorder (MDD) is the most common mental health condition, with a severe decline in performance, disability, and a 15% risk of suicide. Allopurinol increases the level of tryptophan in the body by inhibiting xanthine oxidase, and by elevating the level of tryptophan, i.e., a precursor to serotonin. Accordingly, it can improve the symptoms of depression. This study aimed to investigate the impact of allopurinol on MDD.
Methods & Materials: In this double-blind clinical trial, 70 patients with MDD, diagnosed based on the Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition-Third Edition (DSM IV-TR) were randomly (paired & individual patient records) divided into two equal groups. Both research groups received 40 mg of citalopram daily for 6 weeks. In addition to citalopram, the intervention group received 300 mg allopurinol daily and the control group received a placebo. At the end of the third and sixth weeks, the examined patients were tested for Hamilton Depression Rating Scale (HDRS).
Ethical Considerations: This study was approved by the Ethics Committee of the Arak University of Medical Sciences (Code: IR.ARAKMU.REC.1394.68). Also, it was approved by the Iranian Registry of Clinical Trials (Code: IRCT201508277373n6).
Results:  The Mean±SD HDRS’s score, after 3 weeks of treatment, in the control and allopurinol groups was measured as 28.42±3.1 and 23.02±3.4, respectively. After 6 weeks after treatment, the Mean±SD depression score in the control and allopurinol groups was equal to 23.28±4.1 and 20.4±1.2, in sequence. A significant difference was observed between the research groups; thus, the intervention group obtained a lower mean score in the HDRS than the controls.
Conclusion: Allopurinol can improve the symptoms of depression and can also be used as an adjunct in the treatment of depression.
Full-Text [PDF 3530 kb]   (591 Downloads) |   |   Full-Text (HTML)  (3224 Views)  
Type of Study: Original Atricle | Subject: psychology
Received: 2020/07/26 | Accepted: 2020/12/7

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Arak University of Medical Sciences

Designed & Developed by : Yektaweb